• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeAboutCompany Overview

Company Overview

Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for degenerative diseases ranging from orphan neurodegenerative indications to large market degenerative conditions.

Our scientific team possesses industry-leading knowledge of the natural lipid peroxidation (LPO) process and the role that LPO plays in triggering disease . Based on this unique expertise, we have created a proprietary drug discovery platform that utilizes an elegant chemistry-based solution to create novel, disease-modifying drugs designed to combat the oxidative stress and cellular degeneration that arise from LPO. These first-in-class new chemical entities (NCEs) are isotopically stabilized synthetic versions of polyunsaturated fatty acids (PUFAs) capable of downregulating the LPO process.

Our lead development candidate, RT001, is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) that is in development for infantile neuroaxonal dystrophy (INAD), Friedreich’s ataxia (FA), amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), and progressive supranuclear palsy (PSP). To date, RT001 has been safely administered orally on a daily basis to more than 100 patients, spanning the equivalent of more than 1000 patient exposure months.

RT001 has received a variety of key regulatory designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., these include rare pediatric disease designation for INAD and FA, fast track designation for FA, and orphan drug designation for FA, PSP, and PLA2G6-associated neurodegeneration, which includes INAD. Additionally, in Europe, RT001 has received orphan drug designation for the treatment of INAD.

Our pipeline also includes RT011, an isotopically stabilized, synthetic docosahexaenoic acid (DHA) that is currently advancing toward the clinic for the treatment of dry age-related macular degeneration (AMD), including geographic atrophy.

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM